Visited 48 times, 3 visit(s) today
Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress
Syndax Pharmaceuticals reported Q3 2026 revenue of US$83.3 million versus US$45.87 million a year earlier, with the quarterly net loss at US$49.43 million and basic loss per share at US$0.55. The company also announced a CFO transition effective November 9, 2026. Growing contributions from Revuforj and Niktimvo, alongside pipeline spending that kept the business in




